Private market continues positive upward momentum in AprilForge Private Market Index outperforms public markets as core metrics remain solid.
Private market continues positive upward momentum in April
Trading
Data
Solutions
Insights
About
Frontier Medicines is a precision medicine company that develops breakthrough medicines for patients. Specifically, the company focuses on developing therapies for previously undruggable disease-causing proteins. Through its proprietary Frontier Platform, the company combines scientific approaches that include chemoproteomics, covalent drug discovery, and machine learning. Frontier Medicines was founded in 2018 by Chris Varma Ph.D and headquartered in San Francisco, CA.
Frontier Medicines is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Frontier Medicines pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Frontier Medicines is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 2/22/2024 | Series C | $100MM raised | $XXX.XX | $XXX.XX |
| 7/19/2021 | Series B | $88.5MM raised | $XXX.XX | $XXX.XX |
| 6/25/2019 | Series A-1 and A-2 | $67MM raised | $XXX.XX | $XXX.XX |
